| Identification | Back Directory | [Name]
Benzo[f]quinolin-3(2H)-one, 8-chloro-1,4,4a,5,6,10b-hexahydro-4-methyl-, (4aS,10bS)- | [CAS]
148905-79-7 | [Synonyms]
LY300503
Benzo[f]quinolin-3(2H)-one, 8-chloro-1,4,4a,5,6,10b-hexahydro-4-methyl-, (4aS,10bS)- | [Molecular Formula]
C14H16ClNO | [MOL File]
148905-79-7.mol | [Molecular Weight]
249.74 |
| Hazard Information | Back Directory | [Uses]
LY300503 is an enantiomer of LY191704. LY191704 is a human type I 5α-reductase inhibitor[1][2]. | [in vivo]
LY300503 (30-300 mg/kg; p.o. for 14 d) exhibits the mean dose-normalized AUC value of 56% after the first dose and 38% after the last dose in rats[2]. | [References]
[1] Farid NA, et, al. High-performance liquid chromatographic determination of the enantiomers of the benzoquinolinone LY191704, a human type 1 5 alpha-reductase inhibitor, in plasma. J Chromatogr B Biomed Sci Appl. DOI:10.1016/s0378-4347(96)00383-0
[2] Farid NA, et, al. Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogs. Drug Metab Dispos. 1996 Oct;24(10):1162-5. PMID:8894520 |
|
|